About Us

Vector Laboratories develops, manufactures and markets labeling and detection reagents for immunohistochemistry, immunofluorescence, DNA/RNA and glycobiology. The company serves customers in disease and therapeutics research with tools that help them precisely visualize and study tissues and cells. A pioneer in a number of innovative technologies, Vector Laboratories has been providing a continuous stream of reliable tools for more than 40 years. With headquarters in Burlingame, California and a subsidiary in Peterborough, UK, the company maintains a network of more than 40 distributors across the globe. A privately held company, Vector Laboratories was acquired by Maravai LifeSciences in 2016.

Vector Labs Headquarters

40-Year History of Quality and Innovation

Vector Labs Building

1976

Vector Laboratories is founded

1980

Vector Labs first to commercialize avidin-biotin enzyme complex (VECTASTAIN® ABC kits)

affinity of avidin for biotin

1981

S.M. Hsu published that the high affinity of avidin for biotin could be used to increase the stability of the enzyme antibody complex

1986

Vector Labs launches PHOTOPROBE® Biotin

photoprobe biotin
VECTASHIELD MountingMedia

1993

Vector Labs introduced first antifade mounting media for fluorescence (VECTASHIELD. Mounting Media)

1999

Vector Labs introduced a next-generationPAP pen conforming with environmentalregulations (ImmEdge™ Pen)

Next-Generation PAP Pen
Mouse on Mouse (M.O.M.) Kit

2000

Vector Labs introduces M.O.M. detection kits expanding the use of unconjugated mouse primary antibodies on mouse tissue sections.

2004

Vector Labs expanded antifade mounting media with hardening formulation(VECTASHIELD® HardSet™ Mounting Media)

VECTASHIELD hardset MountingMedia
detextion regents for antigens

2005

Vector Labs developed detection reagents enabling greater access to antigens within tissues and improving multiple antigenlabeling (ImmPRESS™ enzyme polymer)

2007

Vector Labs introduced proprietary substrates enabling multiplexing IHC (ImmPACT™ HRP substrates)

ImmPACT Silo
Bloxall Silo

2011

Vector Labs introduced BLOXALL®Endogenous HRP and AP Blocking Solution

2014

Vector Labs introduced additional proprietary AP substrate (ImmPACT™ Vector® Red substrate)

ImmPACT Vector Red Substrate

2016

Strategic investment by Maravai LifeSciences

2017

Vector Labs introduces Vector® TrueVIEW™ Autofluorescent Quenching Kit

New Web Site

Company Information

Year Founded:
1976
Number of Employees:
Headquarters, R&D and manufacturing in Burlingame, California USA, subsidiary in Peterborough, UK
Facilities:
50+
Number of Products:
600+
Leading Product Groups:
VECTASTAIN® ABC Kits (avidin biotin systems)
ImmPRESS™ Polymer Detection Reagents
Vector® M.O.M. Mouse on Mouse Immunodetection Kits
Enzyme substrates
VECTASHIELD® Antifade Mounting Media
VectaCell™ Live Cell Imaging Reagents and Stains
Secondary fluorescent antibody conjugates
Key Disciplines Served:
Immunohistochemistry
Immunofluorescence
Glycobiology
Immunocytochemistry
Live Cell Imaging
Citations in Scientific Papers:
300,000 +
Trademarks:
ABC-AmP, Animal-Free Blocker, AT-Yellow, BLOXALL, DuoLuX, Elite, EndTag, FastTag, Fusion Aid, GC-Red, HYBEX, ImmEdge, ImmPACT, ImmPRESS, ImmPrint, M.O.M., NeuroBiotin, NicKit p.s.o., PHOTOPROBE, PolyBlock, ProFusion, ProtOn, QuantTag, Resolve-It, UltraSNAP, VECTABOND, VectaCell, VectaMount, VECTASHIELD, VECTASHIELD HardSet, VECTASTAIN, Vector, Vector Black, Vector Blue, Vector NovaRED, Vector Red, Vectrex
Management:
Carl Hull, CEO
Carl has more than 30 years of experience in life science research and diagnostic companies including Abbott Labs, Ventana Medical Systems, Applied Biosystems and Gen-Probe. Carl took over as CEO of Gen-Probe in 2009 and focused the strategy of the company to take full advantage of its core molecular diagnostics and automation strengths. During Carl’s tenure, the company extended its recognized leadership position in the most rapidly growing segment of diagnostics.

Eric Tardif, President
Eric is an experienced investment banker and director with a focus on medical devices, life science tools and diagnostics. Most recently, he was instrumental in the turnaround and sale of Gen-Probe.

David Weber, VP and Chief Commercial Officer
David has an extensive background in directing the commercial functions of a variety of life science tools companies. Most recently, he served as Executive Vice President and Chief Commercial Officer of Affymetrix, where he helped orchestrate that company’s turnaround and ultimate sale to Thermo Fisher Scientific.

Harjit Kullar, VP, Marketing Harjit is an expert in global product marketing, channel sales and brand development. He has more than 15 years of marketing experience with a range of leading life science tools companies.
Contacts for the Media:
Jennifer Dahlgren, Dahlgren Communications
(530) 263-6817
dahlgrenpr@comcast.net

David Weber, Chief Commercial Officer
Maravai LifeSciences
(650) 697-3600
david.weber@maravai.com